Adage Capital Partners
AKRO

Adage Capital Partners’s Akero Therapeutics AKRO Stock Holding History

Adage Capital Partners’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-295,000
Closed -$15.7M – 875
2025
Q2 		$15.7M Buy
295,000
+100,000
+51% +$4.54M 0.03% 507
2025
Q1 		$7.89M Buy
+195,000
New +$8.27M 0.01% 632
2024
Q1 		– Sell
-275,000
Closed -$6.42M – 867
2023
Q4 		$6.42M Sell
275,000
-1,668,009
-86% -$32.9M 0.01% 660
2023
Q3 		$98.3M Sell
1,943,009
-1,105,868
-36% -$51.5M 0.22% 110
2023
Q2 		$142M Buy
3,048,877
+658,986
+28% +$30.2M 0.31% 75
2023
Q1 		$91.4M Buy
2,389,891
+1,064,914
+80% +$47.5M 0.21% 119
2022
Q4 		$72.6M Buy
1,324,977
+452,477
+52% +$19.4M 0.17% 143
2022
Q3 		$29.7M Buy
+872,500
New +$13.3M 0.07% 298
2020
Q1 		– Sell
-540,000
Closed -$12M – 724
2019
Q4 		$12M Buy
540,000
+15,000
+3% +$310K 0.03% 501
2019
Q3 		$11.9M Buy
525,000
+428,279
+443% +$9.97M 0.03% 485
2019
Q2 		$1.85M Buy
+96,721
New +$1.83M ﹤0.01% 666

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners's AKRO Position: Q3 2025 in Review

Adage Capital Partners sold out of Akero Therapeutics (AKRO) in Q3 2025, closing a stake of 295,000 shares — an estimated $15.7M sold.

Adage Capital Partners first reported a position in AKRO in Q2 2019 and held it in 11 quarters. The position peaked at $142M in Q2 2023. 265 funds tracked by Wall St. Rank hold AKRO as of Q3 2025.

  • Adage Capital Partners reported no remaining Akero Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Adage Capital Partners sold 295,000 Akero Therapeutics shares in Q3 2025, an estimated $15.7M.
  • Adage Capital Partners first reported a position in Akero Therapeutics in Q2 2019 and held it in 11 quarters.
  • Adage Capital Partners's Akero Therapeutics position peaked at $142M in Q2 2023.
  • 265 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2025.

Based on Adage Capital Partners's 13F filing for Q3 2025, filed 14 Nov 2025.